Home > Search Results

Results: 20

Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is among the most common types of cancer. Surgical resection is considered the first‐line therapy in early HCC, relapse is the main postoperative problem. A large proportion of participants with HCC have hepatitis B virus infection. Lamivudine with or without adefovir dipivoxil are considered effective and tolerable for chronic hepatitis B by suppressing the viral load and to reduce fibrosis in the liver, and are widely used as adjuvant therapy postoperatively. As yet, there is no evidence that lamivudine with or without adefovir dipivoxil is effective or not for postoperative HCC. The authors found no randomised clinical trials that could be included in the present review. Hence, no conclusions could be drawn.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation

This short report is an update and extension of a technology assessment report published in 2006 on the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alpha (PEG-α) for the treatment of chronic hepatitis B (CHB).

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2009

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation

The aim of this systematic review and economic evaluation was to assess the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alfa-2a (PEG) for the treatment of adults with chronic hepatitis B (CHB) infection. This independent assessment was used by the National Institute for Health and Clinical Excellence (NICE) to issue guidance to the health service in England and Wales on treatment for patients with CHB.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2006

Efficacy and safety of kushenin combined with adefovir dipivoxil in the treatment of chronic hepatitis B: a systematic review

Bibliographic details: Su N, Wu B, Xu T, Tang Y.  Efficacy and safety of kushenin combined with adefovir dipivoxil in the treatment of chronic hepatitis B: a systematic review. Chinese Journal of Evidence-Based Medicine 2010; 10(10): 1182-1187

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Efficacy compared between entecavir and adefovir dipivoxil on HBeAg-positive nucleos(t)ide-naive patients with chronic hepatitis B at week 12 and week 48.

Bibliographic details: Zhao P, Xu D, Wang X, Duan G, Huang L.  Efficacy compared between entecavir and adefovir dipivoxil on HBeAg-positive nucleos(t)ide-naive patients with chronic hepatitis B at week 12 and week 48. Journal of Medical Colleges of PLA 2010; 25(5): 298-306 Available from: http://dx.doi.org/10.1016/S1000-1948(11)60016-6

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Efficacy and safety of telbivudine combined with adefovir dipivoxil for chronic hepatitis B: a systematic review

Bibliographic details: Zhang K, Li Z, Chen H.  Efficacy and safety of telbivudine combined with adefovir dipivoxil for chronic hepatitis B: a systematic review. Chinese Journal of Evidence-Based Medicine 2014; 14(3): 335-340 Available from: http://www.cjebm.org.cn/oa/DArticle.aspx?type=view&id=20140321

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B

OBJECTIVES: The aim of the current study was to compare the effectiveness of adefovir dipivoxil (ADV) monotherapy with that of combination ADV and lamivudine (LAM) therapy in the treatment of LAM-resistant chronic hepatitis B (CHB).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

[The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review]

INTRODUCTION: Chronic hepatitis B is one of the most frequent infectious disease in the world and represents a serious problem of public health

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis

BACKGROUND: Currently, there is no consensus on the efficacy and resistance of de novo combination therapy versus monotherapy for treatment naive patients of chronic hepatitis B (CHB).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus

This well-conducted review evaluated the effectiveness of rescue combination therapy with adefovir dipivoxil plus lamivudine compared with adefovir dipivoxil monotherapy in lamivudine-resistant chronic hepatitis B patients; it found the combination of adefovir dipivoxil plus lamivudine to be superior in inhibiting hepatitis B virus replication and preventing drug resistance. This conclusion is likely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation

This review concluded that adefovir dipivoxil and pegylated interferon alpha were beneficial for patients with Chronic Hepatitis B. Adefovir dipivoxil was beneficial for up to five years with relatively low risk of resistance. The authors' conclusions reflect the evidence, but some included studies were small and there were no consistent statistically significant differences between treatments.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation

This review concluded that adefovir dipivoxil and pegylated interferon alpha-2a are associated with significant improvements in a number of biochemical, virological and histological outcomes in adults with chronic hepatitis B infection. Whilst this was a well-conducted systematic review, the generalisability of the review's findings to patient subgroups routinely encountered in clinical practice is unclear.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Drugs for preventing hepatitis B recurrence after liver transplantation

Chronic hepatitis B is a very common infectious disease leading to chronic liver disease, affecting around 350 million people all over the world. Liver transplantation is often the only viable treatment option. Recurrence of hepatitis B virus (HBV) infection in the liver graft is one of the grave complications of liver transplantation, and to prevent it, hepatitis B immunoglobulin (HBIg) seem associated with improved survival. HBIg and/or antiviral drugs are given alone or in combination after liver transplantation. We attempted to identify the optimal preventive treatment option.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2010

Phyllanthus species for chronic hepatitis B virus infection

Chronic hepatitis B virus (HBV) infection causes significant mortality, morbidity, and economic burden worldwide. Although the current approved therapies are effective, response to treatment is not satisfactory. Patients are at high risk of developing viral resistance, and serious adverse events occur. The objective of this review was to evaluate the benefits and harms of phyllanthus species for patients with chronic HBV infection. Phyllanthus species appear to be safe and may potentially have effects on the clearance of viral markers in patients with HBV infection. However, all of the trials evaluated in this review were of low methodology quality, ie, have high risk of bias, and there was a risk of random errors in the majority of comparisons. Furthermore, all analyses showed substantial heterogeneity. Accordingly, randomised clinical trials with low risk of bias and large sample size should be conducted to confirm the effects of phyllanthus species before clinical use is considered.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

Hepatitis B (Chronic): Diagnosis and Management of Chronic Hepatitis B in Children, Young People and Adults

Chronic hepatitis B describes a spectrum of disease usually characterised by the presence of detectable hepatitis B surface antigen (HBsAg) in the blood or serum for longer than 6 months. In some people, chronic hepatitis B is inactive and does not present significant health problems, but others may progress to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The progression of liver disease is associated with hepatitis B virus (HBV) DNA levels in the blood. Without antiviral treatment, the 5-year cumulative incidence of cirrhosis ranges from 8 to 20%. People with cirrhosis face a significant risk of decompensated liver disease if they remain untreated. Five-year survival rates among people with untreated decompensated cirrhosis can be as low as 15%. Chronic hepatitis B can be divided into e antigen- (HBeAg) positive or HBeAg-negative disease based on the presence or absence of e antigen. The presence of HBeAg is typically associated with higher rates of viral replication and therefore increased infectivity.

NICE Clinical Guidelines - National Clinical Guideline Centre (UK).

Version: June 2013
Show search results within this document

Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation

The study found that treating all patients with chronic hepatitis C without a prior non-invasive liver test (NILT) is cost-effective; however, recently approved interferon-free regimens were not included. For hepatitis B e antigen (HBeAg)-negative patients, this strategy is cost-effective only if the higher cost-effectiveness threshold is appropriate. For HBeAg-positive patients, two NILTs applied sequentially were cost-effective but highly uncertain. No conclusive results could be obtained for alcoholic and non-alcoholic fatty liver disease. Most studies evaluating non-invasive fibrosis tests had a high risk of bias.

Health Technology Assessment - NIHR Journals Library.

Version: January 2015
Show search results within this document

Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis

STUDY OBJECTIVE: To compare the efficacy of nucleoside or nucleotide analog monotherapy for the treatment of chronic hepatitis virus B (HBV) with adefovir dipivoxil, entecavir, lamivudine, telbivudine, and tenofovir disoproxil fumarate.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review

A combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NUCs) is currently recommended as prophylaxis against the recurrence of hepatitis B virus (HBV) after liver transplantation (LT), but the optimal protocol is a matter of controversy. The aim of this study was the identification of factors associated with post-LT HBV recurrence in patients receiving HBIG and NUCs. We searched MEDLINE and PubMed for studies in English about the effectiveness of HBIG and NUCs [lamivudine (LAM) and/or adefovir dipivoxil (ADV)] against post-LT HBV recurrence (January 1998 to June 2010). Forty-six studies, which included 2162 HBV LT recipients, met the selection criteria. Patients receiving HBIG and LAM experienced HBV recurrence more frequently than patients receiving HBIG and ADV with or without LAM [6.1% (115/1889) versus 2.0% (3/152), P = 0.024], although they also were more frequently treated with indefinite HBIG prophylaxis (90% versus 57%, P < 0.001). For patients receiving HBIG and LAM, a lower frequency of HBV recurrence was associated with a high HBIG dosage (≥10,000 IU/day) versus a low HBIG dosage (<10,000 IU/day) during the first week after LT [3.2% (14/440) versus 6.5% (80/1233), P = 0.016], but the HBIG protocol had no impact on HBV recurrence in patients receiving HBIG and ADV. In conclusion, in comparison with the combination of HBIG and LAM, the combination of HBIG and ADV is associated with a lower rate of HBV recurrence after LT. Patients receiving HBIG and LAM should be given a high dosage of HBIG during the first week after LT, but a lower dosage can be used safely in patients receiving HBIG and ADV. Further studies with newer and more potent anti-HBV agents are definitely required.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis

AIM: To investigate the efficacy and safety of combined antiviral and immunosuppressant therapy in adult hepatitis B virus-associated glomerulonephritis (HBV-GN) patients.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Once-a-day highly active antiretroviral therapy: a systematic review

The review assessed once-a-day highly active antiretroviral therapy (HAART) in patients infected with the human immunodeficiency virus. The authors concluded that some once-a-day HAART regimens had a virological efficacy at least similar to that of conventional HAART, an overall CD4 cell increase of at least 114 lymphocytes/microlitre, and good tolerability. The conclusions of this well-conducted systematic review are supported by the evidence presented.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2003

Systematic Reviews in PubMed

See all (35)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...